About Evozyne
Evozyne is a company based in Chicago (United States) founded in 2020 by Andrew Ferguson and Rama Ranganathan.. Evozyne has raised $144.37 million across 4 funding rounds from investors including Fidelity Investments, Paragon Biosciences and Orbimed. Evozyne offers products and services including AI Protein Design Platform and Partnership Pipeline. Evozyne operates in a competitive market with competitors including Nimbus Therapeutics, Cradle, EvolutionaryScale, Profluent Bio and Frontier Medicines, among others.
- Headquarter Chicago, United States
- Founders Andrew Ferguson, Rama Ranganathan
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Evozyne, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$144.37 M (USD)
in 4 rounds
-
Latest Funding Round
$81 M (USD), Series B
Sep 14, 2023
-
Investors
Fidelity Investments
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Evozyne
Evozyne offers a comprehensive portfolio of products and services, including AI Protein Design Platform and Partnership Pipeline. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform that designs novel proteins using Generative AI for medical applications
System for advancing protein therapeutics through investor and advisor partnerships
Unlock access to complete
Unlock access to complete
Scientific Team
6 people
Leadership Team
1 people
Chair Team
1 people
Co Team
1 people
Unlock access to complete
Funding Insights of Evozyne
Evozyne has successfully raised a total of $144.37M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $81 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $81.0M
-
First Round
First Round
(27 Apr 2020)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Debt – Conventional - Evozyne | Valuation |
investors |
|
| Sep, 2023 | Amount | Series B - Evozyne | Valuation | Fidelity Investments , Orbimed | |
| Apr, 2021 | Amount | Series B - Evozyne | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Evozyne
Evozyne has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Paragon Biosciences and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Private equity firm
|
Founded Year | Domain | Location | |
|
Venture capital arm of Nvidia
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Evozyne
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Evozyne
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Evozyne Comparisons
Competitors of Evozyne
Evozyne operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Cradle, EvolutionaryScale, Profluent Bio and Frontier Medicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Chemoproteomics solutions are provided for protein design and development.
|
|
| domain | founded_year | HQ Location |
Provider of an AI models for protein design
|
|
| domain | founded_year | HQ Location |
An AI-based protein design platform is provided for drug discovery.
|
|
| domain | founded_year | HQ Location |
Bioinformatics platform is developed for drug discovery and chemoproteomics.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Evozyne
Frequently Asked Questions about Evozyne
When was Evozyne founded?
Evozyne was founded in 2020.
Where is Evozyne located?
Evozyne is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Is Evozyne a funded company?
Evozyne is a funded company, having raised a total of $144.37M across 4 funding rounds to date. The company's 1st funding round was a Series B of $54.18M, raised on Apr 27, 2020.
What does Evozyne do?
Evozyne has developed novel proteins using protein engineering technology. The company uses machine learning, statistical techniques with high throughput gene synthesis and screening technology to build predictive models of sequence-function relationships for a family of proteins for synthesis, and characterizing of the proteins.
Who are the top competitors of Evozyne?
Evozyne's top competitors include Nimbus Therapeutics, Cradle and Profluent Bio.
What products or services does Evozyne offer?
Evozyne offers AI Protein Design Platform and Partnership Pipeline.
Who are Evozyne's investors?
Evozyne has 5 investors. Key investors include Fidelity Investments, Paragon Biosciences, Orbimed, Valor Equity Partners, and NVentures.